Switching biologics for CRSwNP is frequent in Canadian rhinology; the most common switch is from mepolizumab to dupilumab, with inadequate CRSwNP control driving the switch.
Steroid-Eluting Stents May Not Add Post-Operative Benefit Over Irrigation in Patients with Chronic Sinusitis with Nasal Polyps
For chronic rhinosinusitis with nasal polyps (CRSwNP), with or without asthma, without other underlying systemic disease factors, steroid-eluting stents may not add benefit over steroid rinses.
Novel Medication Delivery System Benefits Postsurgical and Nonsurgical Patients with Chronic Rhinosinusitis with Nasal Polyps
Findings suggest that an exhalation delivery system with fluticasone reduces symptoms and improves quality of life in patients with recurrent symptoms after sinus surgery and patients who have never had surgery.